Trials / Conditions / Relapsed/Refractory Non-Hodgkin Lymphoma
Relapsed/Refractory Non-Hodgkin Lymphoma
5 registered clinical trials studyying Relapsed/Refractory Non-Hodgkin Lymphoma — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118 | Health Institutes of Turkey | Phase 2 / Phase 3 |
| Recruiting | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hod NCT06090539 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignan NCT05880043 | GI Cell, Inc. | Phase 1 / Phase 2 |
| Unknown | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors NCT05320640 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Terminated | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I S NCT03403725 | Menarini Group | Phase 1 |